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with severe mental illness: a systematic reviewEva Kaltenthaler,* Abdullah Pandor and Ruth Wong
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*Corresponding author
Background: Severe mental illnesses (SMIs), such as schizophrenia and bipolar disorder, persist over time
and can cause extensive disability leading to impairments in social and occupational functioning. People
with SMI have higher morbidity and mortality due to physical illness than the general population and may
be more likely to engage in high-risk sexual behaviour (e.g. unprotected intercourse, having multiple
partners, involvement in the sex trade and illicit drug use), putting them at risk of poorer sexual health
outcomes including sexually transmitted infections. Sexual health promotion interventions, developed and
implemented for people with SMI, may improve participants’ knowledge, attitudes, beliefs or behavioural
practices and could lead to a reduction in risky sexual behaviour.
Objectives: To evaluate the effectiveness of sexual health interventions for people with SMI compared
with usual care and their applicability to the UK NHS setting.
Data sources: Thirteen electronic databases were searched from inception to December 2012. All
controlled trials (randomised or non-randomised) that met the following criteria were included: any sexual
health promotion intervention or combination of interventions intended to change the knowledge,
attitudes, beliefs, behaviours or practices of individuals with SMI (deﬁned as adults aged ≥ 18 years who
have received a diagnosis of schizophrenia or bipolar disorder) living in the community.
Review methods: A systematic review of the clinical evidence was undertaken following recommended
guidelines. Data were tabulated and discussed in a narrative review.
Results: Thirteen randomised controlled studies met the inclusion criteria. The methodological quality of
the included studies varied considerably, with only a minority of studies (n = 2) being considered as having
very few methodological limitations. Despite wide variations in the study populations, interventions,
comparators and outcomes, four studies showed signiﬁcant improvements in all measured sexual risk
behaviour outcomes (e.g. human immunodeﬁciency virus knowledge and behaviour change) in the
intervention groups compared with the control groups. In contrast, four studies found signiﬁcant
improvements in the intervention groups for some outcomes only and three studies found signiﬁcant
improvements in certain subgroups only, based on either gender or ethnicity. Finally, two studies reported
no signiﬁcant differences in any sexual risk behaviour outcomes between the intervention and control
groups. Moreover, positive ﬁndings were not consistently sustained at follow-up in many studies.
Limitations: Little detail was provided in the studies regarding the content of interventions, how they
were delivered and by whom, making replication or generalisability difﬁcult.v
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ABSTRACT
viConclusions: Owing to the large between-study variability (especially in the populations, interventions,
comparators and reported outcomes) and mixed results, there is insufﬁcient evidence to fully support or
reject the identiﬁed sexual health interventions for people with SMI. In addition, there are considerable
uncertainties around the generalisability of these ﬁndings to the UK setting. Further research
recommendations include well-designed, UK-based trials of sexual health interventions for people with SMI
as well as training and support for staff implementing sexual health interventions.
Study registration: PROSPERO number CRD42013003674.
Funding: The National Institute for Health Research Health Technology Assessment Programme.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Severe mental illness Severe and long-lasting mental illness associated with functional impairment that
typically involves psychosis (losing touch with reality or experiencing delusions). Someone with a severe
mental illness may nevertheless also have long periods when they are well and are able to manage their
illness. Examples of severe mental illnesses include schizophrenia and bipolar disorder.
Bipolar disorder A severe mental illness with a long course usually characterised by episodes of depression
and also periods of elation and increased activity (mania or hypomania). However, for many people the
predominant experience is of low mood. In its more severe forms, bipolar disorder is associated with
significant impairment of personal and social functioning.
Schizophrenia A major psychiatric disorder, or cluster of disorders, characterised by psychotic symptoms
that alter a person’s perceptions and thoughts and affect their behaviour. Each person with the disorder will
have a unique combination of symptoms and experiences.
Proxy outcome Outcomes used to demonstrate change where a direct measure is not feasible. A proxy
outcome would be used when the outcome of interest cannot feasibly be calculated or when a large sample
size may be required to detect change, e.g. changes in sexual health knowledge, attitudes and intentions
or self-efficacy.xiii
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Severe mental illnesses (SMIs), such as schizophrenia and bipolar disorder, persist over time and can cause
extensive disability leading to impairments in social and occupational functioning. While some individuals
have long periods when they are well and are able to manage their illness, people with SMI have higher
morbidity and mortality due to physical illness than the general population. Many of these individuals will
also have co-existing drug and alcohol problems and difﬁculties in establishing stable and sexual
relationships. These issues mean that they may be more likely to engage in high-risk sexual behaviour such
as unprotected intercourse, having multiple partners, involvement in the sex trade and illicit drug use than
the general population. As a consequence, they are at risk of poorer sexual health outcomes including
sexually transmitted infections such as human immunodeﬁciency virus (HIV) and unintended pregnancies.
Sexual health promotion interventions (such as educational and behavioural interventions, motivational
exercises, counselling and service delivery), developed and implemented for people with SMI, may improve
participants’ knowledge, attitudes, beliefs or behavioural practices (including assertiveness skills) and could
lead to a reduction in risky sexual behaviour.Objectives
The aim of this review was to evaluate the effectiveness of sexual health interventions for people with SMI
and their applicability to the UK NHS setting, and to identify key areas for primary research.Methods
Thirteen electronic databases and research registers were searched from inception to December 2012.
Searches were supplemented by hand-searching relevant articles (including citation searching),
systematic keyword searches of the internet and mental health organisation websites, and contacting
experts in the ﬁeld. The systematic review included all controlled trials (randomised or non-randomised)
that met the following criteria: any sexual health promotion intervention or combination of interventions
(e.g. educational, behavioural, psychological, counselling, etc., delivered at the individual, group or
community level) intended to change the knowledge, attitudes, beliefs, behaviours or practices of
individuals with SMI (deﬁned as adults aged ≥ 18 years who have received a diagnosis of schizophrenia or
bipolar disorder) living in the community. Adults with dementia, personality disorder or intellectual
disability were excluded as they were not included in our deﬁnition of SMI. The methodological quality of
each included study was assessed using the Effective Public Health Practice Project tool for quantitative
studies. Data were tabulated and discussed in a narrative review. A meta-analysis was not possible because
of the heterogeneity of study designs, interventions and types of outcome data available.Results
The literature searches identiﬁed 2590 citations. Of these, 13 randomised controlled studies (representing
14 references) met the inclusion criteria. The methodological quality of the included studies varied
considerably with only a minority of studies (n = 2) being considered as having very few methodological
limitations. The content of the health promotion interventions for improving sexual health varied between
studies but generally included strategies to increase knowledge, assess and reduce sexual health risk,
change behaviour and develop condom skills. The duration of the interventions ranged from four toxvii
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SCIENTIFIC SUMMARY
xviii15 sessions. Standard usual care included educational sessions on HIV, money management, or HIV and
substance misuse, waiting list or no treatment, or health promotion covering a variety of topics. Most
studies included participants with a range of psychiatric diagnoses, which included schizophrenia,
schizoaffective disorder, bipolar affective disorder and major depressive disorders. Despite wide variations
in the study populations, interventions (e.g. programme content and duration), comparators and
outcomes, four studies showed signiﬁcant improvements in all measured sexual risk behaviour outcomes
(e.g. HIV knowledge and behaviour change) in the intervention groups compared with the control groups.
In contrast, four studies found signiﬁcant improvements in the intervention groups for some outcomes
only and three studies found signiﬁcant improvements in certain subgroups only, based on either gender
or ethnicity. Finally, two studies reported no signiﬁcant differences in any sexual risk behaviour outcomes
between the intervention and control groups. Moreover, positive ﬁndings were not consistently sustained
at follow-up in many studies.Discussion and conclusions
Owing to the large between-study variability (especially in the populations, interventions, comparators and
reported outcomes) and mixed results, there is insufﬁcient evidence to fully support or reject the identiﬁed
sexual health interventions for people with SMI. In addition, there are considerable uncertainties around
the generalisability of these ﬁndings to the UK setting as all the evidence is based on studies from the
USA. The ethnic groups represented in the included studies, for example, are not directly comparable to
those in the UK. On account of study heterogeneity, issues with generalisability and the methodological
quality of the included studies, the ﬁndings need to be interpreted with caution. Further research
recommendations include well-designed, UK-based trials of sexual health interventions for people with SMI
and an assessment of the location and costs of proposed services, as well as training and support for staff
implementing sexual health interventions. In addition, patient acceptability of proposed interventions also
needs to be given careful consideration.Study registration
This study is registered as PROSPERO:CRD42013003674.Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18010 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 1Chapter 1 BackgroundDescription of the health problemSevere mental illness (SMI) describes a wide range of major psychiatric disorders (including schizophrenia
and bipolar disorder)1 which persist over time and cause extensive disability leading to impairments in
social and occupational functioning.2 There are occasional inconsistencies in the use of the term and some
studies may include severe anxiety and depressive symptoms and borderline personality. Schizophrenia is
estimated to affect approximately 180,4713 to 220,0004 people in the UK and bipolar disorder
approximately 136,4403 to 297,000.5 The incidence of schizophrenia is higher in men than in women6
whereas bipolar disorder is equally distributed.5 Incidence rates among black and ethnic minority groups
are higher than in a comparable white population.5,6 About 45% of people who receive a diagnosis of
schizophrenia experience recovery after one or more episodes, but about 20% show continuous symptoms
and increasing disability and the remaining 35% show a mixed pattern with varying periods of remission
and relapse.7 For most patients, bipolar disorder is chronic and recurrent. Recovery may or may not be
complete between episodes. Considerable variability exists in the pattern of remissions and relapses;
however, remissions tend to get shorter as time goes on and depressions become more frequent and
longer lasting.5
People with SMI have higher morbidity and mortality due to physical illness than the general population.8,9
De Hert et al.10 reported prevalence rates of several physical illnesses in people with SMI. They found
nutritional and metabolic, cardiovascular, viral, respiratory tract and musculoskeletal diseases as well as
sexual dysfunction, pregnancy complications, stomatognathic diseases and possibly obesity-related cancers
to be more prevalent among people with SMI. Levels of obesity are extremely high among people with
SMI – nearly twice those of the overall population.11 This can have a perceived effect on sexual
attractiveness and consequent functioning. Daumit et al.11 conducted a randomised controlled trial (RCT)
to address this serious problem. The study of overweight or obese adults with SMI used a behavioural
weight loss intervention programme and resulted in signiﬁcantly reduced weight over a period of 18
months in the group of patients receiving the intervention.
Reasons for physical health problems in people with SMI were explored by Robson and Gray,9 who found
that limitations in health services, the effects of having a SMI, health behaviours and the effects of
psychotropic medication may contribute to disparities in health. A systematic review by Tosh et al.12 found
no evidence from RCTs that physical health-care monitoring for people with SMI is useful in preventing
deterioration in physical health and maintaining quality of life, although the authors add that this does not
mean that physical health monitoring does not affect the physical health of people with SMI.
People with SMI are often on medications, which may have an impact on sexual function. The European
Schizophrenia Outpatient Health Outcome (SOHO) study,13 a large prospective, observational study of the
health outcomes associated with antipsychotic treatment in approximately 11,000 outpatients with
schizophrenia in 10 European countries, found that sexually related adverse events were frequent at
baseline before commencing medication and included erectile dysfunction in 40% of men and loss of
libido in 50% of both male and female patients. The study also found that some second-generation
atypical antipsychotics such as olanzapine (ZypAdhera®, Eli Lilly and Company), clozapine (Zaponex®, TEVA
UK) and quetiapine (Seroquel®, AstraZeneca) were signiﬁcantly less likely to result in drug-induced sexual
dysfunction after six months of treatment than other atypical antipsychotics [risperidone (Risperdal
Consta®, Janssen-Cilag Ltd) and amisulpride (Solian®, Sanoﬁ-aventis)]. Montejo et al.14 report in a study of
243 patients with a psychotic disorder that 46% of patients exhibited drug-related sexual dysfunction,
which included 50% of the males and 37% of females in the study. A review by Baggaley15 that looked
at the relative impact of antipsychotics on sexual dysfunction found that risperidone was associated with1
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BACKGROUND
2the greatest level of sexual dysfunction and aripiprazole (Abilify®, Bristol-Myers Squibb) with the least.
Sexual dysfunction included reduced libido, erectile dysfunction, ejaculatory difﬁculties and impaired
orgasm in men and menstrual irregularity/amenorrhoea, reduced libido, impaired orgasm and decreased
vaginal lubrication in women. Various strategies have been suggested for the management of sexual
dysfunction due to antipsychotic drug therapy, including dose reduction, drug holidays, adjunctive
medication and switching to another drug. These options were reviewed by Schmidt et al.,16 who found
little evidence to support these strategies, although sildenaﬁl (Viagra®, Pﬁzer; Revatio®, Pﬁzer), a drug
typically prescribed to men to treat erectile dysfunction, was considered to be a useful treatment option in
men with schizophrenia. Although antipsychotic medication is an important cause of sexual dysfunction in
SMI, Aizenberg et al.17 found that even patients with a diagnosis of schizophrenia who were not receiving
medication exhibited decreased sexual desire. Few studies have examined diagnostic differences and sexual
activity and results have been inconclusive.18
People with SMI are more likely to engage in high-risk sexual behaviour (e.g. unprotected intercourse,
having multiple partners, involvement in the sex trade and illicit drug use), putting them at risk of poorer
sexual health outcomes, including sexually transmitted infections (STIs), e.g. with human immunodeﬁciency
virus (HIV).2,19,20 HIV infection rates among people with SMI have been estimated to be approximately
6.9%, much higher than rates for the general US population for the same time period, estimated to be
0.4%.18 The HIV infection range among those with SMI is reported to be 3–23%, with the highest rates
found among those with SMI and substance abuse disorders.21 Homeless people with SMI were also
reported to have higher rates. Among people with SMI, the age and ethnic distributions of those infected
with HIV appear to be similar to those in the general population, although women with SMI are as likely
as males to be infected with HIV, in contrast to the general US population, in which the ratio of men to
women is 5 : 1.18 A number of risk behaviours are thought to contribute to the higher rates of HIV among
people with SMI, and these include comorbid alcohol and drug use disorders; more frequent same-sex
intercourse than the non-psychiatric population; multiple sex partners; lack of condom use; trading sex for
drugs or money; and transient living circumstances, among others.18 A review of the risk behaviour
associated with people with SMI explored this more fully.2 The authors found 52 studies which showed
that the majority of adults with SMI were sexually active and engaged in risk behaviours associated with
HIV transmission. Correlates of HIV risk were organised into the domains of psychiatric illness, substance
use, childhood abuse, cognitive behavioural factors, social relationships and demographics. Most studies
identiﬁed in this review found that people with a schizophrenia spectrum disorder were signiﬁcantly less
likely to be sexually active compared with those with other major psychiatric disorders. Although many
correlates of HIV risk factors were identiﬁed in this review, the authors suggest caution in view of the
cross-sectional design of many studies and the heavy reliance on univariate analyses. Most studies also
recruited participants from centres where they were receiving treatment; thus, the results may not be
generalisable to people with SMI who do not seek or receive mental health care. Meade et al.22 reviewed
the evidence regarding the relationship between substance abuse and HIV sexual risk behaviour among
people with SMI. The authors concluded that little is known about how substance misuse contributes to
sexual health risk. Gray et al.19 reported that, although people with schizophrenia are more likely than the
general population to engage in high-risk behaviours (e.g. men having sex with men, illicit drug use and
having multiple sexual partners), many health policy reports do not address the risk of HIV in people with
schizophrenia and recommend that research, policy and clinical practice need to be developed to address
this issue.
Many individuals with SMI will also have co-existing drug and alcohol problems23 and difﬁculties in
establishing stable and sexual relationships.9 O’Cleirigh and Safren24 suggest that those with SMI and
substance use disorders present complexities that may be better suited to adapted or modiﬁed models of
cognitive behavioural therapy to support HIV prevention. The authors suggest that these models need to
incorporate design elements of efﬁcacy (such as random assignment) and design elements that support
external validity (such as usual treatment comparison). Individuals with SMI report high rates of childhood
sexual abuse, which is associated with sexual risk behaviour in individuals with SMI as well as in the
general population.25NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18010 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 1Sexual health promotion interventions (such as educational and behavioural interventions, motivational
exercises, counselling and service delivery), developed and implemented for people with SMI, may improve
participants’ knowledge, attitudes, beliefs or behavioural practices (including assertiveness skills) and could
lead to a reduction in risky sexual behaviour.20 McCann26 states that although there have been many
initiatives in the UK to make health and social care more responsive and inclusive, the sexual needs of
individuals with psychosis appear to remain marginalised and neglected. In this study of 30 people with
schizophrenia living in community, 90% of clients felt some need in relation to sexual expression and only
10% of staff recognised sexual expression as a need in their clients.
Two narrative reviews of interventions to improve the sexual health of people with SMI were identiﬁed.
Johnson-Masotti et al.,27 in their review of the clinical effectiveness and cost-effectiveness studies of HIV
prevention interventions, report that the studies identiﬁed in their review have shown only limited success
in helping people with SMI reduce their HIV risk. The cost-effectiveness literature they identiﬁed also
showed mixed results. Higgins et al.20 undertook a review on sexual health education. The authors
identiﬁed six studies that were descriptive or anecdotal, three using post-evaluation or pre–post-evaluation
designs and ﬁve studies with a randomised intervention design. The review found that people who
attended sexual health education programmes which were facilitated in a sensitive and supportive manner
developed attitudes more favourable to condom use, improved intention to avoid unsafe sexual practices,
reduced the number of casual partners and were less likely to engage in unprotected vaginal intercourse.
Education tended to produce a self-reported reduction in sexual risk behaviour as opposed to complete
cessation. Small-group interventions combining information giving, motivational exercises and skills
acquisition were found to be effective in reducing sexual risk behaviour and raising awareness of personal
risk behaviour. The authors highlight the limitations of the included studies such as small sample size,
lack of quality tools tested for reliability and validity and short follow-up periods. Most outcomes were
self-reported and participants were self-selected. Studies did not describe method of random allocation or
provide information on refusal or attrition rates and were mostly conducted in the USA.
Other studies identiﬁed in the literature explored different aspects of sexual health interventions.
Melo et al.28 conducted a cross-sectional national multicentre study throughout Brazil to measure
HIV/acquired immunodeﬁciency syndrome (AIDS) knowledge among patients with mental illness. The study
included 2475 patients from 26 mental health institutions. The authors found that psychiatric patients in
Brazil lag behind the general population with regard to HIV/AIDS knowledge scores. Sikkema et al.21 report
a pilot study involving a community level HIV prevention programme for people with SMI living in
supportive housing. This study of 28 residents involved a cognitive behavioural skills training HIV risk
reduction programme and a 4-month follow-up period. The results were considered promising and
demonstrated signiﬁcant improvements in psychosocial risk factors with indications of sexual behaviour
change at follow-up. DiFranceisco et al.29 looked at differences between completers and early dropouts
from two HIV intervention trials, including one with severely mentally ill participants. Non-attendees in the
SMI group were younger than completers, more likely to associate condom use with positive outcomes
and somewhat more conﬁdent of their ability to negotiate safe sex with their partners. Johnson-Masotti
et al.30 assessed the cost-effectiveness of a RCT by Kelly et al.,31 which had three interventions: single
session, one-on-one, multisession small group and multisession small-group advocates. For men, all three
were found to be cost-effective, with advocacy training the most cost-effective. Cost-effectiveness was
measured using cost–utility analysis in terms of the quality-adjusted life-years saved by the intervention as
a result of preventing participants from becoming infected with AIDS. For women, only the single-session
intervention was cost-effective.
Blank and Hennessy32 explored the feasibility of a reasoned action approach for this population through
the use of two interventions: Preventing AIDS Through Health (PATH), delivered by case managers to
persons with mental illnesses who were HIV negative, and PATH PLUS, delivered by nurses to persons with
mental illness who were HIV positive. The authors concluded that this approach may be useful for
changing behaviour and intentions in people with SMI. As part of the same study, Tennille et al.33
conducted focus groups and interviews with case managers and administrators to determine changes in3
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BACKGROUND
4the service and the case managers as a result of their skills training and experience. Case managers felt
transformed by their training experience and that this improved their understanding of the issues around
sexual health faced by their clients. In a related study by Tennille et al.,34 the researchers held focus groups
with people with mental illnesses to focus on HIV risks and condom use. Participants discussed the sexual
side effects of medication and how this may be associated with HIV risk behaviours, such as not using a
condom. A ﬁnal qualitative study by Solomon et al.35 used rapid assessment procedures to look at HIV
prevention services, and found that case managers had little formalised training on HIV prevention and felt
that doctors or nurses would be better placed to deliver HIV prevention interventions.
The studies described above highlight the challenges and risk of poor sexual health outcomes (including
establishing relationships) encountered by people with SMI, which may be exaggerated by co-existing drug
and alcohol problems. The purpose of this review is to evaluate the effectiveness of sexual health
interventions that may be suitable for people with SMI in the UK.Current service provisionHealth promotion interventions, whether brief interventions or longer-term programmes, are used to
improve various aspects of health and health behaviours. Interventions can be delivered at different levels
(individual, group and community) through an action or group of actions intended to change the
knowledge, attitudes, beliefs or behavioural practices of individuals and populations to reduce their sexual
health risk.36 Individual-level interventions focus on one individual at a time in an attempt to help change
behaviour and may include partner notiﬁcation, individual risk counselling by professionals and detached
education and outreach (for those not accessing mainstream services). Group-level interventions are
delivered to small groups of individuals. Group-level interventions use peer and non-peer models involving
a range of skills, information and support. Community-level interventions are delivered by or within a
deﬁned ‘community’. They seek to improve the risk conditions and inﬂuence behaviour by changing social
norms, policies or characteristics of the environment.36,37
Mental health nurses and other professionals working with people with SMI would be well placed to
include sexual health as part of their contribution to health promotion.20 A study by Apantaku-Olajide et
al.38 used a survey questionnaire to determine mental health patients’ attitude to psychotropic medication
for sexual dysfunction and found that participants were willing to discuss their sexual problems with
health-care professionals. However, staff may require speciﬁc training in order to deliver such interventions.
In a qualitative study of 27 mental health nurses in Ireland, Higgins et al.39 found that the main concerns
reported by the nurses around sexuality were related to feelings of personal and professional vulnerability,
due to a lack of competence, comfort and conﬁdence in this area. Penna and Sheehy40 administered
questionnaires to occupational therapists involved in the care of people with SMI in the UK to determine
their attitudes towards sex education for people with schizophrenia. The majority of occupational
therapists thought sex education was within the domain of their profession but were not providing sex
education currently. The study found that the length of time in practice and knowledge of employers’
policies may inﬂuence this. In NHS Shetland all mental health staff working with people with psychiatric
illnesses receive sexual health training,36 although it is not clear exactly what this training includes and
whether or not this varies with different types of staff.Overall aims and objectives of assessmentThe review will aim to evaluate the following objectives:
1. evaluate the effectiveness of sexual health interventions for people with SMI compared with usual care
and their applicability to the UK NHS setting
2. identify key areas for primary research.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18010 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 1Chapter 2 Assessment of clinical effectiveness
A systematic review of the literature was undertaken to evaluate the effectiveness of sexual healthinterventions for people with SMI compared with usual care. A review of the evidence was undertaken
in accordance with the general principles recommended in the Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) statement (www.prisma-statement.org).Methods for reviewing effectiveness
Identification of studies
Electronic databases
Studies were identiﬁed by searching the following electronic databases and research registers:
l MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R) (Ovid) 1948 to December 2012
l EMBASE (Ovid) 1980 to December 2012
l Cumulative Index to Nursing and Allied Health Literature (CINAHL; EBSCO) 1982 to December 2012
l Cochrane Database of Systematic Reviews (Wiley Online Library) 1996 to December 2012
l Cochrane Central Register of Controlled Trials (CENTRAL; Wiley Online Library) 1898 to
December 2012
l Health Technology Assessment Database (HTA; Wiley Online Library) 1995 to December 2012
l Database of Abstracts of Reviews of Effects (DARE; Wiley Online Library) 1995 to December 2012
l Psychological Information Database (PsycINFO; Ovid) 1806 to December 2012
l Conference Proceedings Index-Science (Web of Science) 1990 to December 2012
l Conference Proceedings Citation Index-Social Science & Humanities (Web of Science) 1990 to
December 2012
l UK Clinical Research Network (CRN) Portfolio Database [National Institute for Health Research (NIHR)]
(www.crncc.nihr.ac.uk)
l ClinicalTrials.gov (US NIH) (www.clinicaltrials.gov)
l The metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com/mrct/).
Sensitive keyword strategies using free text and, where available, thesaurus terms using Boolean operators
and database-speciﬁc syntax were developed to search the electronic databases. Synonyms relating to the
condition (e.g. severe mental illness) were combined with terms for sexual health interventions (e.g. sexual
behaviour, sexually transmitted diseases and sexual health). A pre-deﬁned validated methodological ﬁlter
aimed at restricting search results to controlled trials was used in the searches of MEDLINE, EMBASE,
CINAHL and PsycINFO. Date and language restrictions were not used on any database. An example of the
MEDLINE search strategy is provided in Appendix 2.Other resources
To identify additional published, unpublished and ongoing studies, the reference lists of all relevant studies
(including identiﬁed reviews) were checked for relevant studies and a citation search of relevant articles
(using the Web of Knowledge’s Science Citation Index and Social Science Citation Index) was undertaken
to identify articles that cite the relevant articles. In addition, systematic keyword searches of the internet
and organisational websites, especially in the context of the UK (e.g. Royal College of Psychiatrists, British
Psychological Society, Department of Health, Welsh Assembly Government, International AIDS Society, the
Campbell Collaboration and National Collaborating Centre for Mental Health) were undertaken and key
experts in the ﬁeld were contacted.
All identiﬁed citations from the electronic searches and other resources were imported into and managed
using the Reference Manager bibliographic software, version 12.0 (Thomson Reuters, Philadelphia, PA, USA).5
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ASSESSMENT OF CLINICAL EFFECTIVENESS
6Inclusion and exclusion criteria
The inclusion of potentially relevant articles was undertaken using a two-step process. First, all titles were
examined for inclusion by one reviewer. Any citations that clearly did not meet the inclusion criteria
(i.e. non-human, unrelated to sexual health interventions for people with SMI) were excluded. Second,
all abstracts and full-text articles were examined independently by two reviewers. Any disagreements in
the selection process were resolved through discussion. The relevance of each article for the systematic
review was assessed according to the following criteria.Study design
All controlled trials (randomised or non-randomised) that evaluated sexual health interventions with usual
care for adults with SMI were included. Before-and-after studies without a concurrent control group were
excluded because the absence of a control group to record concurrent changes over time means that
changes due to the intervention or due to temporal trends, concurrent changes or a Hawthorne effect
would be conﬂated. Such studies therefore represent very weak evidence of effectiveness.41,42
Reviews of primary studies were not included in the analysis, but were retained for discussion and
identiﬁcation of additional studies. Moreover, the following publication types were excluded from the
review: animal models; preclinical and biological studies; editorials; opinions; non-English-language papers;
and reports published as meeting abstracts only, where insufﬁcient methodological details are reported to
allow critical appraisal of study quality. Studies from developing countries were also excluded as it is
difﬁcult to generalise (e.g. transferability and acceptability) the characteristics of the effective interventions
to developed countries.Population
The population comprised adults (deﬁned as ≥ 18 years of age) with SMI living in the community and their
carers or staff. SMI was deﬁned as people who have received a diagnosis of schizophrenia or bipolar
disorder.1 Adults with dementia, personality disorder, chronic depression or intellectual disability were
excluded as they are not included in the deﬁnition of SMI.Interventions
Any health promotion intervention or combination of interventions (e.g. educational, behavioural,
psychological, counselling, etc. delivered at individual, group and community levels) intended to change
the knowledge, attitudes, beliefs, behaviours or practices of individuals and populations to improve their
sexual health were included. Interventions that focused on sexual dysfunction and sexual violence or
prescribed drugs were excluded.Relevant comparators
The relevant comparator was considered as standard usual care in the community. This may involve ad hoc
advice on health risks by health-care professionals working with people with SMI, but is not integrated
into routine practice. Studies including active control groups were also included.Outcomes
The outcomes of the review included the following:
l biological: STIs (including HIV), unintended pregnancy
l behavioural: numbers of partners, use of contraception/condoms, uptake of screening or
treatment services
l proxy: knowledge, attitudes and beliefs, barriers and facilitators, intentions, skills.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18010 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 1Data abstraction strategy
Data abstraction was performed by one reviewer into a standardised data extraction form and
independently checked for accuracy by a second. Discrepancies were resolved through discussion.
Where multiple publications of the same study were identiﬁed, data were extracted and reported as a
single study. Where necessary, authors of the included studies were contacted to provide further details
or clariﬁcation.
The following information was extracted for all studies when reported: study characteristics (e.g. author,
year of publication, country, duration of follow-up, funding); participant details (e.g. age, sex, diagnosis,
level of education, marital status, comorbidities); intervention and comparator details (e.g. description,
frequency of measurement, parameters measured); and outcomes (including deﬁnitions).Quality assessment strategy
The methodological quality of each included study was assessed by one reviewer and independently
checked by another. Disagreements were resolved through discussion. The study quality characteristics
were assessed according to (adapted) criteria based on those proposed by the Effective Public Health
Practice Project (EPHPP) (www.ephpp.ca/Tools.html).43 This is a generic tool used to evaluate a variety of
intervention study designs such as controlled trials and observational studies. This tool has been judged
suitable for use in systematic reviews of effectiveness44 and has been reported to have content and
construct validity.43,45 Consideration of study quality included the following six criteria: (1) selection bias –
the extent to which study participants were representative of the target population; (2) study design;
(3) control of confounders; (4) blinding – whether outcome assessors, intervention providers and
participants were aware of the research question; (5) data collection methods; and (6) withdrawals and
dropouts. The six domain-based criteria were each rated as strong, moderate or weak depending on the
characteristics of each criterion reported in the included study. An overall assessment of study quality was
based on the following ratings: studies with at least four criteria rated as ‘strong’ and with no criteria rated
as ‘weak’, were given an overall rating of ‘strong’. Those studies receiving less than four ‘strong’ ratings
and only one ‘weak’ rating were given an overall rating of ‘moderate’. A rating of ‘weak’ was given if two
or more criteria were rated as ‘weak’. Additional study quality criteria included an assessment of
intervention integrity, statistical analysis and generalisability to the UK. Further details of the assessment
tool (and dictionary) are provided in Appendix 3.Methods of data synthesis
Data were tabulated and discussed in a narrative review. A meta-analysis was not possible owing to the
heterogeneity of study designs, interventions and types of outcome data available.Results
Quantity and quality of research available
Number of studies identified and included
The literature searches identiﬁed 2590 citations. Of these, 13 studies (representing 14 references)31,46–58
met the inclusion criteria. These studies were all deﬁned by the authors as RCTs. A ﬂow chart describing
the process of identifying relevant literature can be found in Figure 1.7
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FIGURE 1 Study flow chart (adapted PRISMA diagram).
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A total of 20 full-text articles were excluded as they did not meet all the pre-speciﬁed inclusion criteria.
The majority of the articles were excluded primarily on the basis of inappropriate study design (not
controlled clinical trials),21,28,32–35,40,59,60 incorrect population (adolescents,61 inpatients only62 or patients
without SMI),63,64 outcomes not identiﬁed in the protocol,65–67 not available68,69 or unsuitable publication
type (reviews, commentaries or editorials).70,71 Of the two studies that were not available, one study
appeared to be a conference abstract69 of an included study (Susser et al.56). The other study,68 which was
identiﬁed on a trials register, was a planned open-label RCT that was designed to evaluate the
effectiveness of motivational interviewing plus skill-building exercises compared with behavioural
skill-building exercises alone in reducing HIV risk behaviour in people with SMI. Although the authors of
the study were contacted, no further details were forthcoming, including information on study completion
(and if the results were unpublished) or recruitment failure. A full list of excluded studies with reasons for
exclusion is presented in Appendix 4.Description of included studies (design and study characteristics)
The study characteristics of the included studies are shown in Table 1 and presented as described in the
studies. All studies were published between 1996 and 2012, included populations with mental illness and
were conducted in the USA. It should be noted that not all studies used the term ‘severe mental illness’,
with other descriptions used including ‘chronically mentally ill outpatients’ (Katz et al.52 and Kalichman
et al.51). The population groups are brieﬂy described in Table 1. Sample sizes ranged from 20 (Weinhardt
et al.58) to 408 (Carey et al.49) patients. Study populations were recruited from different settings and
included homeless shelters (Berkman et al.,46,47 Linn et al.53 and Susser et al.56), outpatient psychiatric
clinics [Berkman et al.,48 Carey et al.,49 Kalichman et al.,51 Kelly et al.,31 National Institute of Mental Health
(NIMH),57 Otto-Salaj et al.55 and Weinhardt et al.58], residential facilities in a community setting
(Collins et al.50), a drop-in socialisation centre (Katz et al.52), and a treatment programme for substance
misusers (Malow et al.54). Length of follow-up ranged from 2 weeks (Katz et al.52) to 18 months
(Susser et al.56).
The content of the health promotion interventions for improving sexual health varied and included
strategies to increase knowledge, assess and reduce sexual health risk, change behaviour and develop
condom skills. These are more fully described in Table 1. Sex, Games and Videotapes (SexG) was used in
two studies (Linn et al.53 and Susser et al.56), while variations of SexG were used in two additional studies
including SexG-Brief (Berkman et al.46,47) and enhanced SexG (Berkman et al.48). Other studies included HIV
risk reduction programmes (Carey et al.,49 Katz et al.52 and Kelly et al.31), HIV prevention interventions
(Collins et al.,50 Kalichman et al.51 and Otto-Salaj et al.55), enhanced cognitive behavioural skill building
(Malow et al.54), a sexual assertiveness intervention (Weinhardt et al.58) and Project LIGHT (Living in Good
Health Together), covering HIV prevention and reduction (NIMH57). The duration of the intervention
sessions ranged from four (Kalichman et al.51 and Katz et al.52) to 15 sessions (Susser et al.56).
The standard care in the control groups included educational sessions on HIV (Berkman et al.,46,47
Kelly et al.,31 Linn et al.53 and NIMH57), money management (Berkman et al.,48 Collins et al.50 and Susser
et al.56) or HIV and substance misuse (Carey et al.49), waiting list or no treatment (Kalichman et al.,51
Katz et al.52 and Weinhardt et al.58), or health promotion covering a variety of topics (Malow et al.54 and
Otto-Salaj et al.55).
Sources of funding were not reported in four studies (Berkman et al.,46,47 Katz et al.52 and Weinhardt
et al.58). The majority of studies were funded at least in part by the NIMH in the USA.9
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18Patient characteristics of included studies
The patient characteristics of the included studies are shown in Table 2. With regard to the gender of
study participants, ﬁve studies included males only (Berkman et al.,46,47 Berkman et al.,48 Linn et al.,53
NIMH57 and Susser et al.56) and two included females only (Collins et al.50 and Weinhardt et al.58). The
remaining studies included both men and women and ranged from 45% (Malow et al.54) to 52% male
(Kalichman et al.51) One study did not report the percentage of male and female participants although the
authors stated that the ratio of male to female participants was 2 : 1 (Katz et al.52).
Most studies, apart from two (Katz et al.52 and NIMH57) reported the percentage of participants with
psychiatric diagnoses which included schizophrenia, schizoaffective disorder, bipolar affective disorder and
major depressive disorder. Although the Katz et al.52 study did not include percentages, the authors stated
that the majority of patients were diagnosed with schizophrenia or bipolar disorder. It is worth noting that
some studies included other diagnoses, such as mood, anxiety and personality disorders31 and other
undeﬁned illnesses.53,55,56 The percentage of participants with schizophrenia or schizoaffective disorder
varied widely between the studies and ranged from 15.7% (Malow et al.54) to 85% (Kalichman et al.51).
The studies varied in how they reported the age of the study participants. Eight of the 13 studies reported
the mean age of the participants which varied from 33.7 (Kelly et al.31) to 42.3 years (Collins et al.50). The
age range in the included studies was only reported in two studies, with the widest range (22–59 years)
reported by Katz et al.52 Three studies (Linn et al.,53 NIMH57 and Susser et al.56) reported only the
percentage of participants above or below a certain age.
There was also variation in the ethnicity of participants between the studies, with seven studies reporting
the majority of participants to be African Americans (Berkman et al.,46,47 Berkman et al.,48 Linn et al.,53
Malow et al.,54 NIMH,57 Otto-Salaj et al.55 and Susser et al.56). One study did not report information on the
ethnicity of the participants.52 Only four studies reported information regarding the marital status of
participants (Berkman et al.,48 Carey et al.,49 Kalichman et al.51 and Malow et al.54). Most of the studies
provided at least some information on the educational level of participants, apart from two studies
(Berkman et al.46,47 and Katz et al.52) which provided no information. Nine of the 13 studies reported some
information regarding comorbidities, which was usually substance misuse, and four studies (Carey et al.,49
Kelly et al.,31 Otto-Salaj et al.55 and Weinhardt et al.58) provided no information.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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The overall methodological quality of the 13 included studies is summarised in Table 3 and Appendix 5.
Generally, only two studies (Linn et al.53 and Susser et al.56) were considered as having very few
methodological limitations. All studies, except one (NIMH57), selected participants who were ‘somewhat
likely’ to be representative of the target population; however, most studies (54%) did not report the
number of individuals who were eligible to participate (Berkman et al.,47 Berkman et al.,48 Kalichman
et al.,51 Malow et al.,54 Otto-Salaj et al.55 and NIMH57) or reported very low numbers of eligible individuals
who agreed to participate in the study (Carey et al.49).
Although all the studies were described as RCTs, only three studies reported the method of randomisation
(Berkman et al.,48 Collins et al.50 and Susser et al.56). In seven studies confounders were well controlled
(Carey et al.,49 Kalichman et al.,51 Linn et al.,53 Malow et al.,54 Otto-Salaj et al.,55 Susser et al.56 and
Weinhardt et al.58); however, in the remaining studies (Berkman et al.,47 Berkman et al.,48 Collins et al.,50
Katz et al.,52 Kelly et al.,31 and NIMH57) no details were provided on baseline compatibility or whether a
variable was associated with the intervention or exposure and causally related to the outcome of interest.
None of the studies was graded as ‘strong’ for blinding. Only ﬁve studies (Berkman et al.,48 Carey et al.,49
Linn et al.,53 Malow et al.54 and Susser et al.56) blinded the outcome assessors and protected against
detection bias.TABLE 3 Summary of methodological quality. Review of authors’ judgements about each methodological quality
item for each included study
Author,
year
Selection
bias
Study
design Confounders Blinding
Data
collection
Withdrawals
and dropouts
Overall
rating
Berkman
et al., 200646,47
Moderate Strong Weak Moderate Strong Strong Moderate
Berkman
et al., 200748
Moderate Strong Weak Moderate Strong Strong Moderate
Carey et al.,
200449
Weak Strong Strong Moderate Strong Strong Moderate
Collins et al.,
201150
Moderate Strong Weak Moderate Strong Strong Moderate
Kalichman
et al., 199551
Moderate Strong Strong Moderate Strong Weak Moderate
Katz et al.,
199652
Moderate Strong Weak Moderate Strong Weak Weak
Kelly et al.,
199731
Moderate Strong Weak Moderate Weak Weak Weak
Linn et al.,
200353
Moderate Strong Strong Moderate Strong Strong Strong
Malow et al.,
201254
Moderate Strong Strong Moderate Strong Moderate Moderate
NIMH, 200657 Weak Strong Weak Moderate Weak Strong Weak
Otto-Salaj
et al., 200155
Moderate Strong Strong Moderate Weak Strong Moderate
Susser et al.,
199856
Moderate Strong Strong Moderate Strong Strong Strong
Weinhardt
et al., 199858
Moderate Strong Strong Moderate Strong Weak Moderate
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24All studies failed to provide details on whether or not study participants were aware of the research
question (reporting bias). Reliable and valid outcome measures were used in most (77%) of the studies
(Berkman et al.,47 Berkman et al.,48 Carey et al.,49 Collins et al.,50 Kalichman et al.,51 Katz et al.,52
Linn et al.,53 Malow et al.,54 Susser et al.56 and Weinhardt et al.58). While three studies (Kalichman et al.,51
Kelly et al.31 and Weinhardt et al.58) failed to provide details of withdrawals and dropouts, the follow-up
rate was 80% or greater in eight studies (Berkman et al.,47 Berkman et al.,48 Carey et al.,49 Collins et al.,50
Linn et al.,53 Otto-Salaj et al.,55 Susser et al.56 and NIMH57). Intervention integrity (assurance that the
intervention was delivered according to plan) is an important part of programme delivery. Only ﬁve studies
(Collins et al.,50 Kalichman et al.,51 Linn et al.,53 Otto-Salaj et al.55 and Susser et al.56) reported that > 80%
of participants received the allocated intervention and eight studies measured the consistency of the
intervention (Carey et al.,49 Collins et al.,50 Kalichman et al.,51 Kelly et al.,31 Linn et al.,53 Otto-Salaj et al.,55
Susser et al.56 and NIMH57), which was considered satisfactory. Contamination or co-intervention was
unlikely in three studies (Berkman et al.,47 Kalichman et al.51 and Linn et al.53), likely in one study
(Collins et al.50) and not reported in nine studies (Berkman et al.,48 Carey et al.,49 Katz et al.,52 Kelly et al.,31
Malow et al.,54 Otto-Salaj et al.,55 Susser et al.,56 NIMH57 and Weinhardt et al.58).
No studies reported a sample size calculation. Many of the studies had small sample sizes so it is likely
they had inadequate statistical power to detect between-group differences, even if these were present.
The statistical analysis in most studies was appropriate and used intention-to-treat analysis. All the
included studies were conducted in the USA, thus making generalisability of the ﬁndings to the UK
setting uncertain.Study outcomes
Sexual risk behaviours were stated to be the main outcome of the studies apart from Otto-Salaj et al.,55
which listed HIV risk behaviours as the primary outcome (Table 4). How sexual risk behaviours were
measured varied between the studies. Five studies (Berkman et al.,46,47 Berkman et al.,48 Collins et al.,50
Linn et al.53 and Susser et al.56) included vaginal episode equivalent (VEE) scores in the reported outcomes.
The VEE score is weighted on the basis of statistical estimates of the relative risk of various sexual
behaviours (unprotected vaginal, anal and oral sex). A greater weight is assigned to unprotected anal sex
(2 points) than unprotected vaginal sex (1 point), and also allows for some contribution from unprotected
oral sex (0.1 points). A VEE score is calculated by summing VEE points for various sexual behaviours over a
designated period of time.72 A wide range of other outcomes included the total number of sexual
partners, number of casual partners, unprotected anal, vaginal or oral sex, self-report of sexually
transmitted diseases, condom use, knowledge, attitudes, intentions, assertiveness and motivation.
Three studies (Berkman et al.,48 Katz et al.52 and NIMH57) reported no information regarding number of
participants completing at least part of the intervention. It was unclear in Linn et al.53 how many
participants completed all sessions although the authors stated that all participants were available for
follow-up at 6 months. Kelly et al.31 reported the mean number of sessions only and Susser et al.56
reported that all participants completed the initial 6-month study period. The remaining studies reported
the percentage of participants who completed either all sessions or at least some of the sessions, as shown
in Table 4.Effects of interventions
This section provides a narrative summary of the results by the following sexual health-related outcomes:
biological, behavioural and proxy. Further details are provided in Tables 4 and 5.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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TABLE 5 Types of outcomes reported in the studies
Outcome type Speciﬁc outcome Studies
Biological STI (including HIV) Carey et al., 200449
Unintended pregnancy None
Behavioural Number of partners or episodes of
unprotected intercourse
Berkman et al., 200646,47
Berkman et al., 200748
Carey et al., 200449
Collins et al., 201150
Kelly et al., 199731
Linn et al., 200353
Malow et al., 201254
NIMH, 200657
Otto-Salaj et al., 200155
Susser et al., 199856
Use of contraception None
Use of condoms Kalichman et al., 199551
Linn et al., 200353
Malow et al., 201254
NIMH, 200657
Otto-Salaj et al., 200155
Susser et al., 199856
Uptake of screening or treatment services None
Proxy Knowledge, attitudes and beliefs Carey et al., 200449
Kalichman et al., 199551
Katz et al., 199652
Kelly et al., 199731
Malow et al., 201254
Otto-Salaj et al., 200155
Weinhardt et al., 199858
Barriers and facilitators None
Intentions Carey et al., 200449
Kalichman et al., 199551
Otto-Salaj et al., 200155
Weinhardt et al., 199858
Skills Carey et al., 200449
Weinhardt et al., 199858
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ASSESSMENT OF CLINICAL EFFECTIVENESS
32Biological outcomes
The biological outcomes included in the protocol were STIs (including HIV) and unintended pregnancy.
Only one study (Carey et al.49) reported information on STIs, with the intervention group reporting
signiﬁcantly fewer new STIs than the control group. No studies reported information on
unintended pregnancies.Behavioural outcomes
Four behavioural outcomes were included in this review: number of partners, use of contraception, use of
condoms and uptake of screening or treatment services. No studies were identiﬁed reporting information
on the use of contraception or uptake of screening or treatment services. Seven studies reported
information on the number of partners (Carey et al.,49 Kelly et al.,31 Linn et al.,53 Malow et al.,54 NIMH,57
Otto-Salaj et al.55 and Susser et al.56), with two of these studies49,31 reporting patients having signiﬁcantly
fewer partners in the intervention groups than the control groups. The other studies showed no difference
between the intervention and control groups with regard to the number of partners.
Indirectly related to number of partners is the number of episodes of unprotected intercourse, which was
reported in six studies. Kelly et al.31 found signiﬁcant changes in risk-related behaviours such as
unprotected sex and number of sexual partners in the intervention group, which included advocacy
training. Three studies found no signiﬁcant improvements or differences in the reported VEE scores (which
included the number of unprotected episodes of intercourse) between the intervention and control groups
(Berkman et al.,46,47 Berkman et al.48 and Collins et al.50). In contrast, Linn et al.53 and Susser et al.56 found
signiﬁcant improvements in VEE scores in the intervention groups compared with the control groups.
With regard to use of condoms, six studies reported some information on condom use. Kalichman et al.51
and Susser et al.56 both reported a signiﬁcant increase in the frequency of condom use in the intervention
groups, and Linn et al.53 also reported a greater proportion of encounters protected by condom use.
Malow et al.54 reported signiﬁcant improvements in condom use skills in males only in the intervention
group, whereas Otto-Salaj et al.55 found a signiﬁcant percentage of intercourse occasions protected by
condoms for females only in the intervention group. The NIMH57 study found signiﬁcantly greater condom
use for African Americans only in the intervention group.Proxy outcomes
The proxy outcomes included in the review were knowledge, attitudes and beliefs; intentions; skills; and
barriers and facilitators. No studies reported outcomes that were related to barriers and facilitators to
sexual health interventions.
Carey et al.49 reported more positive condom attitudes and stronger condom use intentions, improved HIV
knowledge and improved behavioural skills in the intervention group. Kalichman et al.51 reported that the
intervention group demonstrated signiﬁcant gains in knowledge and intention to change risk behaviour.
Kelly et al.31 reported improvements in AIDS risk behaviour knowledge for all groups with the greatest
improvement in both intervention groups. Malow et al.,54 however, found no improvement in HIV
knowledge but did ﬁnd an improvement in intentions regarding sexual attitudes for males only in the
intervention group. Katz et al.52 also found that the intervention group demonstrated signiﬁcant
improvement in knowledge about AIDS. Otto-Salaj et al.55 reported improvements in HIV knowledge for
men only, improvements in attitudes for condom use for women only and no signiﬁcant change in HIV risk
reduction behaviour intentions. Weinhardt et al.58 found improvements in sexual assertiveness, knowledge
and HIV risk reduction behaviour although no difference was found with regard to behavioural intentions.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Despite wide variations in the study populations, interventions (e.g. programme content and duration),
comparators and outcomes, four studies49,51,52,56 showed signiﬁcant improvements in all measured sexual
risk behaviour outcomes (e.g. HIV knowledge and behaviour change) compared with the control groups.
In contrast, four studies31,50,53,58 found signiﬁcant improvements in the intervention groups for some
outcomes only and three studies found signiﬁcant improvements in subgroups only, based on either
gender54,55 or ethnicity.57 Finally, two studies46–48 reported no signiﬁcant differences in any sexual risk
behaviour outcomes between the intervention and control groups. Moreover, positive ﬁndings were not
consistently sustained at follow-up in many studies. These mixed results are similar to those reported in
other previous reviews of the literature.20,27 In addition, in a systematic review of sexual health
improvement interventions, conducted by Fullerton and Burtney73 for NHS Scotland, the authors concluded
that there was insufﬁcient evidence to fully support or reject the identiﬁed sexual health interventions for
people with SMI. The ﬁndings from this systematic review reinforce this view.Strengths and limitations of the assessmentAlthough an extensive literature search was conducted, it is possible that some relevant studies may have
been missed. However, such omissions are likely to have been minimal, as the search included all
identiﬁable publications in the grey literature (including contact with clinical experts in the ﬁeld). Another
limitation is that the initial screening was undertaken by only one reviewer and relevant studies may have
potentially been missed.
Many of the studies included in the systematic review included participants with major depression, which
was not included in the deﬁnition of SMI used for this review, which only included bipolar disorder and
schizophrenia. Many studies also included participants with schizoaffective disorder, which again was not
part of our initial deﬁnition of SMI. It was not possible to differentiate results for patients with different
diagnoses reported in the studies. Patients with major depression may respond differently to interventions
than those with bipolar disorder or schizophrenia, or indeed there may be differences between these two
diagnoses. Another issue related to diagnosis is the lack of uniformity in determining how the diagnoses
were made.
Little detail was provided in the studies regarding the content of interventions, how they were delivered
and by whom, making replication or generalisability difﬁcult. The control groups used in the studies often
included components of the intervention such as education or were not appropriate controls; for example,
the control group may have received one session where the intervention group received six or more.
This makes it difﬁcult to assess the true effectiveness of the intervention. It was not always clear in the
studies what the primary outcomes were and whether or not data from all recorded outcomes were
reported. This could potentially result in outcome reporting bias.74 In addition, the follow-up periods
reported in the studies varied and were often quite short, ranging from 2 weeks to 18 months, and
positive results were often diminished at follow-up assessments. The main threats to validity in this group
of patients relate to study outcomes and participants. Most outcomes were measured by self-reporting
and participants self-selecting, thus raising the possibility of bias and recall problems.20
Although none of the studies reported that it had been designed to have adequate power to assess
differences in subgroups, some reported differences in results between male and female participants.33
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DISCUSSION
34This issue needs to be explored further as there may be differences between male and female responses to
sexual health interventions. There was also a lack of data and analysis reported in the studies regarding
the relationship between education levels and outcomes, as well as that between the age of the
participants and outcomes, both of which are important variables in the context of sexual health.
In general, the studies identiﬁed were mostly considered to be of moderate quality although there were
issues in the methods of randomisation, which were often not fully described. Other limitations were:
limited blinded assessment of outcomes; little information provided regarding loss of participants to
follow-up; no power calculations reported; and small sample sizes in most studies. Only some studies used
validated instruments to collect data on outcomes and most relied on self-report of these outcomes. Little
information was provided in any of the studies regarding acceptability to participants or those delivering
the interventions. There was also little information provided regarding the feasibility of the interventions
and how much they would cost to implement. None of the studies provided any information on
unintended pregnancies, use of contraception, uptake of screening or treatment services, or facilitators
and barriers to providing interventions.Assessment of factors relevant to the NHS and other partiesThere are considerable uncertainties around the generalisability of these ﬁndings to the UK setting as the
evidence is based on studies from the USA. In addition, the ethnic groups represented in the included
studies are not directly comparable to those in the UK. Nevertheless, several factors discussed above are
relevant to implementing sexual health interventions for people with SMI in the NHS. These include
consideration of who will deliver the interventions and where they will be delivered. There needs to be an
assessment of whether or not sexual health interventions could be integrated into the current care
provision provided for people with SMI on the NHS. White et al.75 described an ongoing study to assess
ways that physical comorbidity in SMI could be addressed by mental health nurses working in NHS
community mental health teams. Lessons may be learned from this research that could be incorporated
into sexual health intervention programmes.
The choices made regarding location of sexual health services for people with SMI will have resource
implications. Likewise, whether or not interventions are delivered to groups of participants or individually
will have resource implications and the potential to impact on the effectiveness of the intervention. The
follow up of patients also needs to be taken into account as many of the included studies in the review
showed a diminished impact at follow-up. Higgins et al.20 suggested the need for an ongoing process
rather than a single intervention.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18010 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 1Chapter 4 ConclusionsImplications for service provisionDespite the methodological limitations and variations in the populations, sexual health interventions, use of
control groups and outcomes measured in the included studies, the overall ﬁndings were mixed, with only
4 of the 13 studies showing signiﬁcant beneﬁts in sexual risk behaviour interventions (e.g. HIV knowledge
and behaviour change) compared with control groups in people with SMI living in the community. In view
of study heterogeneity, issues with generalisability and the methodological quality of the included studies,
the ﬁndings need to be interpreted with caution. Recommendations for further research are listed below.Suggested research priorities
Primary research
Further research in this area should incorporate the following.
l UK-based trials of sexual health interventions for people with SMI should be conducted. These need to
be well designed (use clear methods of randomisation and blinded outcome assessment) and
appropriately powered.
l Care needs to be given to the selection of patients and their diagnoses need to be clearly recorded.
Sample sizes need to be large enough to ensure that analyses for each relevant subgroup of patients
are possible or studies need to be conducted with recruitment of patients with a single diagnosis.
Methods of recruitment need to be standardised, transparent and clearly reported. Comorbidities and
other treatments need to be reported.
l Interventions should be clearly described and could potentially include behavioural skills, relationship
development, condom use and other issues. Controls also need to be clearly described and should
include usual care. If active control groups are included, then the components of these groups need to
be clearly described.
l Reliable and valid tools for measuring outcomes are needed. Alternatives to measures of self-report
need to be considered.
l Follow-up periods need to be long enough to determine how long change can be maintained. The
optimal duration of studies requires further research. The provision of ‘booster’ sessions and long-term
interventions needs to be considered.Other issuesl Staff training should include support for communicating sexual health messages and attitudes towards
such work. Research is needed to ﬁnd the most cost-effective way of providing this.
l The location of services needs to be given consideration and whether or not sexual health interventions
can be incorporated into existing services.
l The costs of providing sexual health interventions need to be addressed and should include the
incorporation of any savings from reduced incidence of STIs.
l The acceptability of sexual health interventions to people with SMI needs to be researched.35
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SEVERE MENTAL ILLNESS29 January 2013.1. Title of the project:What is the effectiveness of sexual health interventions for people with severe mental illness?2. Name of TAR team and project ‘lead’School of Health and Related Research (ScHARR), The University of Shefﬁeld.
Project lead:
Dr Eva Kaltenthaler, Reader in Health Technology Assessment, Health Economics and Decision Science,
ScHARR, University of Shefﬁeld, Regent Court, 30 Regent Street, Shefﬁeld S1 4DA3. Plain English SummarySevere mental illness describes a wide range of major psychiatric disorders (including schizophrenia and
bipolar disorder)1 which persist over time and cause extensive disability leading to impairments in social
and occupational functioning.2 People with severe mental illness have higher morbidity and mortality due
to chronic disease than the general population,3 and are more likely to engage in high-risk sexual
behaviour (e.g. unprotected intercourse, multiple partners, sex trade and injection drug use), putting them
at risk of worse sexual health outcomes including sexually transmitted infections, including HIV.2,4 Many of
these individuals will also have coexisting drug and alcohol problems5 and have difﬁculties in establishing
stable and sexual relationships.6 Sexual health promotion interventions (such as educational and
behavioural interventions, motivational exercises, counselling and service delivery), developed and
implemented for people with severe mental illness, may improve participants’ knowledge, attitudes,
beliefs or behavioural practices (including assertiveness skills) and could lead to a reduction in risky sexual
behaviour.4 The aim of this review is to evaluate the effectiveness of sexual health interventions for
people with severe mental illness, its applicability to the UK NHS setting, and identify key areas for
primary research.4. Decision problem
Purpose of the decision to be made
The assessment will address the question ‘What is the effectiveness of sexual health interventions for
people with severe mental illness?’Clear definition of the intervention
Health promotion interventions, whether brief interventions or longer term programmes are used to
improve various aspects of health and health behaviours. Interventions can be delivered at different levels45
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46(individual, group and community) through an action or group of actions intended to change the
knowledge, attitudes, beliefs, or behavioural practices of individuals and populations to reduce their sexual
health risk.7 Individual level interventions focus on one individual at a time in an attempt to help change
behaviour and may include partner notiﬁcation, individual risk counselling by professionals and detached
education and outreach (for those not accessing mainstream services). Group level interventions are
delivered to small groups of individuals. Group level interventions use peer and non-peer models involving
a range of skills, information and support. Community level interventions are delivered by or within a
deﬁned ‘community’. They seek to improve the risk conditions and inﬂuence behaviour by changing social
norms, policies or characteristics of the environment.7,8Place of the intervention in the treatment pathway(s)
Mental health nurses and other professionals working with people with SMI would be well placed to
include sexual health as part of their contribution to health promotion.4 However, staff may require
speciﬁc training in order to deliver such interventions.Relevant comparators
The relevant comparator is considered as usual care in the community. Professionals working with people
with severe mental illness may currently provide ad hoc advice on health risks, but this is not integrated
into routine practice.Population and relevant sub-groups
The population will include any adults (deﬁned as ≥ 18 years of age) of either gender living in the
community with severe mental illness and their carers/staff. As recommended in the vignette (produced by
NETSCC HTA), severe mental illness is deﬁned as people who have received a diagnosis of schizophrenia
or bipolar disorder.1 The identiﬁcation of subgroups will be governed by the available evidence. However,
on a priori grounds, information will be sought from people with dual diagnoses, that is, those with severe
mental illness plus substance abuse.Key factors to be addressed
The review will aim to evaluate the following objectives:
1. Evaluate the effectiveness of sexual health interventions for people with severe mental illness compared
with usual care and its applicability to the UK NHS setting.
2. Identify key areas for primary research5. Report methods for synthesis of evidence of
clinical effectivenessA review of the evidence for clinical effectiveness will be undertaken systematically following the general
principles recommended in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement (http://www.prisma-statement.org/). The review will assess the effectiveness of sexual
health interventions for people with severe mental illness compared with usual care.Inclusion/Exclusion criteria:
Population
The population will comprise adults (deﬁned as ≥ 18 years of age) with severe mental illness living in the
community and their carers/staff. Severe mental illness is deﬁned as people who have received a diagnosis
of schizophrenia or bipolar disorder. Adults with dementia, personality disorder, or mental retardation will
be excluded as they are not included in our deﬁnition of severe mental illnessNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18010 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 1Interventions
Any health promotion intervention or combination of interventions (e.g. educational, behavioural,
psychological, counselling etc. delivered at the individual, group and community level) intended to change
the knowledge, attitudes, beliefs, behaviours or practices of individuals and populations to improve their
sexual health will be considered. Interventions that focus on sexual dysfunction and sexual violence or
prescribed drugs will be excluded.Comparators
Usual care (deﬁned as standard community care)Outcomes
The outcomes of the review will include the following:
l Biological: sexually transmitted infections (including HIV), unintended pregnancy
l Behavioural: numbers of partners, use of contraception/condoms, uptake of screening or
treatment services
l Proxy: knowledge, attitudes and beliefs, barriers and facilitators, intentions, skillsSearch strategy
A comprehensive search will be undertaken to systematically identify clinical effectiveness literature on
sexual health interventions for people with severe mental illness.The search strategy will comprise the
following main elements:
l Searching of electronic databases
l Contact with experts in the ﬁeld
l Scrutiny of bibliographies of all retrieved papers
A list of the electronic databases and grey literature sources that will be searched is provided in Table 1.
The search strategy will be adapted across the databases and language and date restrictions will not be
applied. However, due to the large number of potentially relevant citations, searches in the major
databases will be restricted by study type (i.e. controlled trials). An example of the MEDLINE search
strategy is provided in Section 9.TABLE 1 Data sources – electronic databases and grey literature
Electronic database sources
l MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R) (Ovid) 1948 to present
l EMBASE (Ovid) 1980 to present
l Psychological Information Database PsycINFO (Ovid) 1806 to present
l The Cochrane Library including the Cochrane Database of Systematic Reviews (CDSR), Cochrane Register of Controlled
Trials (CENTRAL), Health Technology Assessment (HTA) and Database of Abstracts of Review of Effects (DARE)
Databases 1898 to present
Grey literature and internet sources
l ISI Web of Knowledge Conference Proceedings Index
l UK Clinical Research Network (CRN) Portfolio Database (http://www.crncc.nihr.ac.uk/)
l ClinicalTrials.gov (http://www.clinicaltrials.gov/)
l metaRegister of Controlled Trials (mRCT) (http://www.controlled-trials.com/mrct/)
l Websites - societies and mental health organisations will include the following:
¢ Royal College of Psychiatrists (http://www.rcpsych.ac.uk/)
¢ British Psychological Society (http://www.bps.org.uk/)
¢ International Aids Society (http://www.iasociety.org/)
¢ National Collaborating Centre for Mental Health (www.nccmh.org.uk)
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48Inclusion criteria
All controlled trials (randomised or non-randomised) that evaluate sexual health interventions with usual
care for adults with severe mental illness will be included. In the absence of trial evidence, other study
designs such as observational cohort studies with a contemporaneous control group will be considered
and identiﬁed via iterative searching methods.9 Before and after studies without a concurrent control
group will be excluded because the absence of a control group to record concurrent changes over time
means that changes due to the intervention or due to temporal trends, concurrent changes or a
Hawthorne effect would be conﬂated. Such studies therefore represent very weak evidence of
effectiveness.10,11
The inclusion of potentially relevant articles will be undertaken using a two-step process. First all titles will
be examined for inclusion by one reviewer (any citations that clearly do not meet the inclusion criteria
i.e. non-human, unrelated to sexual health interventions for people with severe mental illness will be
excluded). Second, all abstracts and full text articles will be examined independently by two reviewers.
Any disagreements in the selection process will be resolved through discussion.Exclusion criteria
Reviews of primary studies will not be included in the analysis, but will be retained for discussion and
identiﬁcation of additional studies. Moreover, the following publication types will be excluded from the
review: animal models; preclinical and biological studies; narrative reviews, editorials, opinions; non-English
language papers and reports published as meeting abstracts only, where insufﬁcient methodological
details are reported to allow critical appraisal of study quality. Studies from developing countries will also
be excluded as it will be difﬁcult to generalise (e.g. transferability and acceptability) the characteristics of
the effective interventions to developed countries. Details of all full text excluded papers (including
non-English language citations) will be provided in the review.Data extraction strategy
Data will be extracted by one reviewer using a standardised data extraction form and independently
checked for accuracy by a second. Uncertainties will be resolved by discussion. Where multiple publications
of the same study are identiﬁed, data will be extracted and reported as a single study.Quality assessment strategy
The methodological quality of each included study will be assessed according to (adapted) criteria based
on those proposed by Effective Public Health Practice Project (http://www.ephpp.ca/Tools.html). This is a
generic tool used to evaluate a variety of intervention study designs such as RCTs and observational
studies. This tool has been judged suitable to be used in systematic reviews of effectiveness12 and has been
reported to have content and construct validity.13,14 Consideration of study quality will include the
following factors: (1) selection bias; (2) study design; (3) confounders; (4) blinding; (5) data collection
method; (6) withdrawals/dropouts; (7) intervention integrity; (8) statistical analysis; and (9) generalisability.Methods of analysis/synthesis
Data will be tabulated and discussed in a narrative review. If appropriate (i.e. populations, interventions
and outcomes are comparable), meta-analysis will be employed to estimate a summary measure of effect
on relevant outcomes based on intention to treat analyses. Meta-analysis will be undertaken using ﬁxed or
random effects models, using STATA Statistical Software or the Cochrane Collaboration Review Manager
Software, for example. Heterogeneity will be explored through consideration of the study populations,
methods and interventions, by visualisation of results and, in statistical terms, by the χ2 test for
homogeneity and the I2 statistic. However, it is anticipated that heterogeneity of study designs and
interventions, and the type of data available, may mean that it is not appropriate to perform meta-analysis.
The likely form of analysis will be a narrative synthesis.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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TAR Centre
The ScHARR Technology Assessment Group (ScHARR-TAG) undertakes reviews of the effectiveness and
cost-effectiveness of healthcare interventions for the NHS R&D Health Technology Assessment Programme
on behalf of a range of policy makers in a short timescale, including the National Institute for Health and
Clinical Excellence. A list of our publications can be found at: http://www.shefﬁeld.ac.uk/scharr/sections/
heds/collaborations/scharr-tag/reports.
Much of this work, together with our reviews for the international Cochrane Collaboration, underpins
excellence in healthcare worldwide.7. Competing interests of authorsThe following authors do not have any competing interest: Eva Kaltenthaler, Abdullah Pandor, Ruth Wong,
Professor Wylie and Dr Smith.
Professor Gray has received speaker fees and honoraria from companies (Wyeth, BMS, Otsuka, Janssen-
Cilag, Eli Lilly and AstraZeneca) that manufacture products that can potentially impact on sexual
functioning. He is also funded by the National Institute of Health Research to undertake a trial to promote
physical (including sexual) health in patients with mental illness.8. Timetable/milestonesMilestone
Draft protocol 14 December 2012
Final protocol 14 January 2013
Progress report 1 March 2013
Assessment report 29 March 20139. Appendices
9.1 Draft search strategy (Ovid MEDLINE)1. ((chronic$ or sever$ or persist$) and mental$ and (ill$ or disorder$)).mp.
2. exp Schizophrenia/
3. (schizo$ or hebephreni$ or oligophreni$ or psychotic$ or psychosis or psychoses).tw.
4. Paranoid Disorders/
5. exp Psychotic Disorders/
6. (paranoia or paranoid disorders or psychotic disorders or psychosis).tw.
7. exp Bipolar Disorder/
8. ((bipolar or bi polar) adj5 (disorder$ or depress$)).tw.
9. (hypomania$ or mania$ or manic$).tw.
10. (((cyclothymi$ or rapid or ultradian) adj5 cycl$) or RCBD).tw.
11. or/1-10
12. exp Sexual Behavior/
13. (sex* and (health or safe or safer or unsafe or risk or high-risk or unprotected or abstinence or
behaviour* or behavior* or activit* or partner*)).mp.49
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5014. exp Sexually Transmitted Diseases/
15. ((STI or STIs or STD or STDs) and (incidence or prevalen* or prevent* or control* or risk* or
reduc*)).mp.
16. ((sexually transmitted disease* or sexually transmitted infection*) and (incidence or prevalen* or
prevent* or control* or risk* or reduc*)).mp.
17. or/12-16
18. Randomized controlled trials as Topic/
19. Randomized controlled trial/
20. Random allocation/
21. randomized controlled trial.pt.
22. Double blind method/
23. Single blind method/
24. Clinical trial/
25. exp Clinical Trials as Topic/
26. controlled clinical trial.pt.
27. or/18-26
28. (clinic$ adj25 trial$).ti,ab.
29. ((singl$ or doubl$ or treb$ or tripl$) adj (blind$ or mask$)).tw.
30. Placebos/
31. Placebo$.tw.
32. (allocated adj2 random).tw.
33. or/28-32
34. 27 or 33
35. Case report.tw.
36. Letter/
37. Historical article/
38. 35 or 36 or 37
39. exp Animals/
40. Humans/
41. 39 not (39 and 40)
42. 38 or 41
43. 34 not 42
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a MEDLINE exampleDatabase searched: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R)
Platform or provider used: Ovid SP
Date of coverage: 1948 to December 2012
Search undertaken: 6 December 20121. ((chronic$ or sever$ or persist$) and mental$ and (ill$ or disorder$)).mp.
2. exp Schizophrenia/
3. (schizo$ or hebephreni$ or oligophreni$ or psychotic$ or psychosis or psychoses).tw.
4. Paranoid Disorders/
5. exp Psychotic Disorders/
6. (paranoia or paranoid disorders or psychotic disorders or psychosis).tw.
7. exp Bipolar Disorder/
8. ((bipolar or bi polar) adj5 (disorder$ or depress$)).tw.
9. (hypomania$ or mania$ or manic$).tw.
10. (((cyclothymi$ or rapid or ultradian) adj5 cycl$) or RCBD).tw.
11. or/1-10
12. exp Sexual Behavior/
13. (sex* and (health or safe or safer or unsafe or risk or high-risk or unprotected or abstinence or
behaviour* or behavior* or activit* or partner*)).mp.
14. exp Sexually Transmitted Diseases/
15. ((STI or STIs or STD or STDs) and (incidence or prevalen* or prevent* or control* or risk* or
reduc*)).mp.
16. ((sexually transmitted disease* or sexually transmitted infection*) and (incidence or prevalen* or
prevent* or control* or risk* or reduc*)).mp.
17. or/12-16
18. Randomized controlled trials as Topic/
19. Randomized controlled trial/
20. Random allocation/
21. randomized controlled trial.pt.
22. Double blind method/
23. Single blind method/
24. Clinical trial/
25. exp Clinical Trials as Topic/
26. controlled clinical trial.pt.
27. or/18-26
28. (clinic$ adj25 trial$).ti,ab.
29. ((singl$ or doubl$ or treb$ or tripl$) adj (blind$ or mask$)).tw.
30. Placebos/
31. Placebo$.tw.
32. (allocated adj2 random).tw.
33. or/28-32
34. 27 or 33
35. Case report.tw.
36. Letter/53
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38. 35 or 36 or 37
39. exp Animals/
40. Humans/
41. 39 not (39 and 40)
42. 38 or 41
43. 34 not 42
44. 11 and 17 and 43NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Reproduced with the permission of Thomas B, Ciliska D, Dobbins M, Micucci S. A process forsystematically reviewing the literature: providing the research evidence for public health nursing
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with rationaleAuthor, year Reason for exclusion
Brady, 200868 Not available (from Trials register – author contacted but no reply)
Brown, 200961 Adolescents
Blank et al., 201232 Not RCT (pooled analysis)
Collins et al., 199669 Not available
Collins et al., 200162 Inpatients only
Colom et al., 200365 No sexual health promotion outcomes
Craig et al., 200466 No sexual health promotion outcomes
Goldberg et al., 200959 Not RCT
Hafner et al., 198367 No sexual health promotion outcomes
Holder, 199970 Comment/discussion
Mansergh et al., 201063 Not SMI
Markowitz et al., 200064 Not SMI
Melo et al., 201028 Not RCT
Penna and Sheehy, 200040 Not RCT
Peters and Nierenberg, 201171 Review
Sikkema et al., 200721 Not RCT
Solomon et al., 200735 Not RCT
Tennille et al., 200934 Not RCT
Tennille et al., 201033 Not RCT
Weinhardt et al., 199760 Not RCT69
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